login
  Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page
 

Fluoroscopy times and radiation exposure during renal denervation compared to coronary procedures


Thursday, 15 Mar 2012 10:36

A retrospective analysis conducted in Germany shows that fluoroscopy times and radiation exposure in patients undergoing renal denervation are similar to those in patients undergoing routine diagnostic catheterisation with elective percutaneous coronary intervention but lower than in patients undergoing emergency intervention. The results were showed in a poster presentation at ISET in Miami, USA.


Ionising radiation carries an oncogenic risk which is linearly related to the dose and is closely related to procedural time. An estimation of the effective dose can be obtained from the measurements of the dose-area product, which is a measure of stochastic risk and a potential quality indicator,” the authors, led by Frank Himmel, Medizinische Klinik II, Universitätsklinikum Schleswig-Holstein, Lübeck, wrote.


The aim of the study was to assess fluoroscopy time, radiation exposure (dose area-product) and contrast dye consumption in patients undergoing renal denervation to treat medically resistant hypertension in comparison to diagnostic catheterisation and percutaneous coronary intervention.


A retrospective analysis of renal denervation therapy and adult cardiac percutaneous procedures (consecutive patients between January to May 2011 undergoing coronary angiography and ventriculography) was carried out to determine procedural characteristics and the dose-area product. The investigators identified four groups: group 1 (n=790, coronary angiography); group 2 (n=141, elective percutaneous coronary intervention in stable patients); group 3 (n=160, emergency percutaneous coronary intervention in acute coronary syndrome patients), group 4 (n=54, patients undergoing renal denervation). Dose-area product meter attached to the X-ray unit was used for the estimation of the radiation dose received by the patient during the procedures. In average renal denervation therapy consisted of 6–9 bilateral ablations spots.


The results showed that in the renal denervation group fluoroscopy time, dose-area product and contrast dye consumption were 10±1sec, 4878±456cGy cm2 and 141±6mL, respectively. In the elective percutaneous coronary intervention, fluoroscopy time was 11±1sec, dose-area product was 7457±421cGy cm2, and contrast dye consumption was 136±5mL. In emergency percutaneous coronary intervention patients, fluoroscopy time was 12±1sec, dose-area product was 9046±482cGy cm2, and contrast dye consumption was 213±6±5mL.


The authors concluded that the radiation dose varies substantially across different types of procedures and up to tenfold within the same procedure. “The enhanced knowledge of radiation dose might help the cardiologist to implement radiation sparing procedures minimising patient and operator radiation hazards in renal denervation,” they wrote.

 

 

Results (mean±standard error of the mean)

Body weight (kg)

Fluoroscopy time (sec)

Dose-area product (cGy cm2)

CDC (mL)

Group 1 (coronary angiography)

82±1

5±0.6

3514±99

99±1

Group 2 (elective PCI)

84±1

11±1*

7457±421*

136±5*

Group 3 (emergency PCI)

82±1

12±1*

9046±482*+

213±6*+

Group 4 (renal denervation)

92±3*

10±1*

4878±456*

141±6*

 

* p<0.05 vs. group 1, + p<0.05 vs. group 2




Add New Comment

Related Items


Most popular


First patient enrolled in Vessix sham-controlled study
Friday, 17 Apr 2015
Boston Scientific has announced that it is taking a new approach to evaluate the performance of its Vessix renal Denervation System. It says it is initiating a study with a novel design to isolate ... First patient enrolled in Vessix sham-controlled study

CardioCel to feature at prominent heart valve conferences
Wednesday, 01 Apr 2015
Admedus’ CardioCel will be featured in a number of presentations at the American Association for Thoracic Surgery Mitral Conclave 2015 meeting and the 95th AATS Annual Meeting. CardioCel to feature at prominent heart valve conferences

PICSO system has potential to improve myocardial recovery after PCI
Thursday, 09 Apr 2015
The first safety and feasibility study of pressure-controlled intermittent coronary sinus occlusion (PICSO) in the setting of ST-segment elevation myocardial infarction indicates that the system ... PICSO system has potential to improve myocardial recovery after PCI

Features


Tips and tricks for achieving optimum results with a drug-coated balloon
Thursday, 07 May 2015
With drug-coated balloons, we may have been able to deliver a device to the lesion, but we were not always sure how much drug we actually delivered. Fortunately, because of this problem, there have ... Tips and tricks for achieving optimum results with a drug-coated balloon

Robotic PCI could be used to reduce radiation exposure to the operator
Thursday, 09 Apr 2015
Ryan Madder, an interventional cardiologist at the Frederik Meijer Heart & Vascular Institute (Spectrum Health, Grand Rapids, Michigan, USA) explains why he believes a robotic system (CorPath, C... Robotic PCI could be used to reduce radiation exposure to the operator

Profiles


Flavio Ribichini
Thursday, 05 Mar 2015
Flavio Ribichini speaks to Cardiovascular News about being involved in the first use of primary ... Flavio Ribichini

Sunil Rao
Thursday, 23 Oct 2014
Sunil Rao speaks to Cardiovascular News about his career highlights, including his research into ... Sunil Rao

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions